Moxonidine

Moxonidine acts as a selective agonist at central imidazoline I1 receptors. Activation of these receptors decreases sympathetic nervous system activity, which reduces norepinephrine release, leading to lower heart rate, reduced vascular tone, and ultimately a drop in systemic blood pressure.

The appropriate dose of Moxonidine is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Moxonidine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Moxonidine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike ACE inhibitors or calcium‑channel blockers, Moxonidine lowers blood pressure by reducing central sympathetic outflow via imidazoline I1 receptors. This mechanism can be advantageous for patients who experience side effects with other classes, but clinical choice depends on individual patient factors and comorbidities.

Moxonidine tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources.

Moxonidine is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, bradycardia, hepatic dysfunction, and rare allergic reactions. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, jaundice, rash, or swelling of the face or throat.

Moxonidine is contraindicated in patients with known hypersensitivity to the drug, severe hepatic impairment, or those who are taking other centrally acting antihypertensives that could cause excessive blood‑pressure reduction without medical supervision.